Dr. Yardley is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
SCRI Oncology Partners
335 24th Ave North, Suite 200
Nashville, TN 37203Phone+1 615-329-7640Fax+1 615-234-4033
Education & Training
- University of Texas Southwestern Medical CenterFellowship, Hematology and Medical Oncology, 1991 - 1994
- University of Texas Southwestern Medical CenterResidency, 1988 - 1991
- Medical College of Georgia at Augusta UniversityClass of 1988
Certifications & Licensure
- TN State Medical License 2000 - 2025
- TX State Medical License 1989 - 2005
Publications & Presentations
PubMed
- Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial.Sherene Loi, Roberto Salgado, Giuseppe Curigliano, Roberto Iván Romero Díaz, Suzette Delaloge
Nature Medicine. 2025-01-21 - 6 citationsAdjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Corre...Paolo Tarantino, Nabihah Tayob, Guillermo Villacampa, Chau Dang, Denise A Yardley
Journal of Clinical Oncology. 2024-11-01 - Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (...Adrienne G Waks, Emily L Chen, Noah Graham, Anna Mae Frey, Kenneth Almeida
JCO Oncology Practice. 2024-07-19
Press Mentions
- FDA Expands Approval of Breast Most Cancers Drug Kisqali to Earlier Stage SufferersSeptember 17th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: